pcos treatment glp-1 The dual impact of receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials GLP-1 agonists and PCOS weight
Description
When it comes to risks, most are rare but are still something to consider before beginning treatment
GI side effects to monitor
Cost varies, but many insurers require prior authorization
In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication
